🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Linköping
Clinical trial register · Sweden

Clinical Trials in Linköping, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Sweden and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2213 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
2213
Studies in scope
all four open statuses
1238
Recruiting now
open to new participants
367
Lead sponsors
across recruiting studies
Top sites
Stockholm 32 Uppsala 25 Lund 21 Gothenburg 20 Linköping 15
Narrow the registerReset
Recruitment status
Phase
Site location
Stockholm32 Uppsala25 Lund21 Gothenburg20 Linköping15
All 32 locations
Target enrolment
to

Trials with a site in Linköping

15 of 2213 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Sweden
Start
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
500
Linköping, Lund, Mölndal, Örebro, Stockholm
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Falun, Gothenburg, Karlstad, Linköping, Lund, Örebro, Stockholm, Uppsala
2026-08-21
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Linköping, Lund, Solna, Umeå, Uppsala
2025-12-29
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
AstraZeneca
Phase 3
473
Gothenburg, Linköping, Lund, Stockholm, Uppsala
2025-06-10
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Huddinge, Karlstad, Linköping, Stockholm, Uppsala, Vaxjo
2025-03-03
Active, closed
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
NCT06681324Crohn's Disease
AstraZeneca
Phase 2
24
Linköping, Stockholm
2024-12-11
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Linköping, Stockholm
2024-08-28
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Gävle, Gothenburg, Linköping, Rättvik, Stockholm, Uppsala
2024-03-29
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Gothenburg, Linköping, Rättvik, Stockholm, Uppsala
2023-11-07
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Eskilstuna, Linköping, Stockholm, Uppsala
2015-11-03
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca
Phase 3
682
Linköping
2015-10-21
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Gothenburg, Linköping, Malmö, Solna, Stockholm, Umeå
2014-04-22
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca
Phase 3
510
Linköping, Örebro, Uppsala
2013-09-25
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Swedish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-sweden/city/link-ping

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Sweden and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,213 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Linköping that also match the filters currently applied.

How many clinical trials are recruiting in Linköping?

5 of the 15 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Linköping), 15 studies
PhaseStudiesRecruitingShare
Phase 313586.7%
Phase 22013.3%

Most active sponsors

Lead sponsors with the most studies (Linköping)
Lead sponsorStudiesRecruiting
AstraZeneca155
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.